Jigarkumar Parikh

Assistant Professor

Jigarkumar Parikh

Assistant Professor

Academic Appointment(s)

Medical College of Georgia
Department of Medicine: Hematology and Oncology

Bio

Dr. Parikh graduated from Baroda Medical College in India and completed his Bachelor of Medicine and Bachelor of Surgery in 2002. He was a resident in Pathology at Baroda Medical College from 2003 to 2005. Dr. Parikh completed his residency in Internal Medicine and fellowship in Hematology and Oncology at Augusta University, prior to joining the faculty as Assistant Professor if Medicine in 2011. Dr. Parikh has become a member of multiple professional societies over his career. In 2008, he became a member of the National Comprehensive Cancer Network and American College of Physicians. In 2011, he became a member of American Society of Hematology and American Society of Clinical Oncology. Dr. Parikh has given many presentations, including: ‘Advances in HER-2 targeted therapies in breast cancer’, ‘Targeted therapy in non-small cell lung cancer’, ‘Are there distinct sub-phenotypes of sickle cell disease? and ‘Traumatic pulmonary pseudo cyst in an 18 year old wrestler’.

  • (706) 721-2505
  • BA 5407

Education

  • MBBS, Medicine Maharaja Sayajirao University, 2002

Certifications

  • Hematology Board 2016

  • Medical Oncology Board 2015

  • American Board of Internal Medicine (ABIM) 2011

  • Educational Commission for Foreign Medical Graduates (ECFMG) 2006

  • PHY GA Composite Medical Board, 2011

Awards & Honors

  • Exemplary Teaching Award 2016-2017 2016

  • MCG Exemplary Teaching Award 2015-2016 MCG, 2015

Courses Taught Most Recent Academic Year

  • RHON 5000

    Hematology-Oncology
  • RMED 5000

    Medicine
  • GMED 5000

    Basic Clkshp Med Pt 1
  • GMED 5100

    Basic Clkshp Med Pt 2
  • GMED 5012

    Hematology/Oncology Extn.

Scholarship

Selected Recent Publications

  • Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition, 2017
    Journal Article, Academic Journal
  • Efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study, 2017
  • A Case Report of Inflammatory Syndrome Presenting as Tumor Lysis Syndrome after Single Dose of Nivolumab, 2017
  • Radiation and Immunotherapy Extended Life in a patient who Failed Chemotherapy and Immunotherapy Trials: Implications of Radiation Abscopal Effect, 2016
  • Recurrent Adult Choroid Plexus Carcinoma Treated with High-Dose Chemotherapy and Syngeneic Stem Cell (Bone Marrow) Transplant, 2013